PERFORMANCE OF MODIFIED RODNAN SKIN SCORE IN EARLY DIFFUSE CUTANEOUS SCLERODERMA-ANALYSIS FROM 4 COHORTS

Abstract

Background The modified Rodnan skin score (mRSS) is used as a primary outcome measure in clinical trials of dcSSc. EUSTAR analysis has proposed that a lower mRSS and earlier disease duration are associated with progressive disease, as defined by worsening mRSS [1]. Objectives 1. To find an optimal cut off for worsening mRSS in 4 cohorts of dcSSc, and 2. To assess if presence of anti-RNA polymerase III [RNAP] vs. anticentromere /or anti-SCL-70 is associated with different mRSS cut off for worsening disease. Methods We used 4 cohorts with early dcSSc (defined as ≤60 months from 1st non-RP sign or symptom) – 2 US cohorts [Combined Response Index in Systemic Sclerosis [CRISS] and Prospective Reg..